LATEST ALERTS
Partisan gridlock continues to keep Congress from taking action on clarifying the regulatory framework for CBD. Even as the Biden administration moves to reschedule cannabis down to a more permissive classification – one it could share with something as ubiquitous as Tylenol with codeine – Congress punts the issues surrounding CBD back and forth with the US Food and Drug Administration (FDA).
And this inaction is having a concrete effect. For example, cannabinoids still remain under-explored – due in large part to being relatively unaddressed within the legal landscape.
